Cyclerion Therapeutics Inc

NASDAQ:CYCN   3:55:39 PM EDT
2.58
-0.06 (-2.27%)
Other Pre-Announcement

Cyclerion Updates On Timing Of Results Of Olinciguat Phase 2 Study In Sickle Cell Disease Patients

Published: 10/01/2020 12:00 GMT
(CYCN) - Cyclerion - Update on Timing of Results of Olinciguat Phase 2 Strong Study in Sickle Cell Disease Patients & Iw-6463 Translational Pharmacology Study.
Cyclerion - Due to Covid-19 Related Operational Delays in Obtaining Certain Study Data, Continues to Perform Analyses of Data From Both Studies.
Cyclerion Therapeutics Inc - Expects to Communicate Top Line Results From Both These Studies in the Coming Weeks.